Popular Trials
Procedure
NUV-868 + Olaparib/Enzalutamide for Cancer
Recruiting1 awardPhase 1 & 2
Fairfax, Virginia
This trial tests a new drug, NUV-868, taken regularly by mouth, in patients with advanced cancers. It aims to find the best dose and see if combining it with other drugs can improve treatment. The study includes patients with advanced solid tumors and a specific type of prostate cancer.
Angiogenesis Inhibitor
Cediranib + Olaparib for Ovarian and Breast Cancer
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing the combination of two drugs, cediranib maleate and olaparib, to treat patients with certain types of recurrent cancer. Cediranib maleate cuts off the blood supply to cancer cells, while olaparib stops them from repairing their DNA. The trial aims to find the best dose and see if the combination works better than using olaparib by itself. Combining cediranib, which cuts off the blood supply to cancer cells, with olaparib, which stops cancer cells from repairing their DNA, may help patients live longer without their cancer getting worse.
Popular Filters
Trials for Breast Cancer Patients
Monoclonal Antibodies
SGN-B7H4V for Advanced Cancers
Recruiting1 awardPhase 1
Denver, Colorado
This trial tests a new drug called SGN-B7H4V for safety and side effects in patients with advanced or metastatic solid tumors. It aims to find the right dosage and see if the drug can effectively treat their cancer.
Monoclonal Antibodies
MK-7684A for Advanced Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Chemotherapy
BMS-986340 + Nivolumab/Docetaxel for Cancer
Recruiting1 awardPhase 1 & 2
Hackensack, New Jersey
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
Immune Checkpoint Inhibitor
Olaparib + Pembrolizumab for Breast Cancer
Recruiting1 awardPhase 2
Monterey, California
This trial is comparing the efficacy of two different treatments for triple negative breast cancer - olaparib plus pembrolizumab versus chemotherapy plus pembrolizumab. The primary hypotheses are that olaparib plus pembrolizumab will be superior to chemotherapy plus pembrolizumab in terms of progression-free survival and overall survival.
Trials for LABC Patients
Monoclonal Antibodies
SGN-B7H4V for Advanced Cancers
Recruiting1 awardPhase 1
Denver, Colorado
This trial tests a new drug called SGN-B7H4V for safety and side effects in patients with advanced or metastatic solid tumors. It aims to find the right dosage and see if the drug can effectively treat their cancer.
Monoclonal Antibodies
MK-7684A for Advanced Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Chemotherapy
BMS-986340 + Nivolumab/Docetaxel for Cancer
Recruiting1 awardPhase 1 & 2
Hackensack, New Jersey
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
Immune Checkpoint Inhibitor
Olaparib + Pembrolizumab for Breast Cancer
Recruiting1 awardPhase 2
Monterey, California
This trial is comparing the efficacy of two different treatments for triple negative breast cancer - olaparib plus pembrolizumab versus chemotherapy plus pembrolizumab. The primary hypotheses are that olaparib plus pembrolizumab will be superior to chemotherapy plus pembrolizumab in terms of progression-free survival and overall survival.
Trials for ER Positive Patients
Monoclonal Antibodies
Pembrolizumab + Mifepristone for Breast Cancer
Recruiting1 awardPhase 2
Chicago, Illinois
This trial is testing a combination of two drugs to treat advanced breast cancer. The first part of the trial will test the safety of the combination in ten patients. If the combination is safe, the trial will expand to include more patients.
Chemotherapy
Personalized Adaptive Novel Agents for Breast Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is testing new medicines along with regular cancer treatment to find the best combinations for breast cancer patients. It focuses on identifying which treatments work best based on specific cancer characteristics. Early signs of success are monitored using MRI scans and tests on blood and tissue samples.
Monoclonal Antibodies
DS-1062a for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
Los Angeles, California
This trial tests a new drug, DS-1062a, on patients with advanced cancers who haven't been cured by other treatments. The goal is to find the safest dose and see if the drug can help treat these cancers.
DHODH Inhibitor
Leflunomide for Triple Negative Breast Cancer
Recruiting1 awardPhase 1 & 2
New York, New York
This trial is testing the safety and effectiveness of leflunomide, a daily oral medication, in women with aggressive triple negative breast cancer. The drug aims to block a substance that helps cancer cells grow. The study focuses on women who have already tried other treatments.
Trials for PD-L1 Positive Patients
Chemotherapy
KFA115 + Tislelizumab for Advanced Cancers
Recruiting1 awardPhase 1
Toronto, Ontario
This trial tests a new drug, KFA115, alone and with pembrolizumab in patients with advanced cancers. It aims to find the safest dose and see if the drugs can reduce tumors. The focus is on patients whose cancers are hard to treat with current options.
PD-L1 Inhibitor
SGN-PDL1V for Cancer
Recruiting1 awardPhase 1
San Antonio, Texas
This trial is testing a new drug, SGN-PDL1V, alone and with pembrolizumab, in patients with advanced solid tumors. The goal is to see if these treatments are safe and effective. SGN-PDL1V targets cancer cells directly, while pembrolizumab helps the immune system fight the cancer.
Chemotherapy
Combination Therapies for Breast Cancer
Recruiting1 awardPhase 1 & 2
Germantown, Tennessee
This trial is testing multiple immunotherapy-based treatment combinations to see if they are effective and safe in patients with metastatic or inoperable TNBC. The study will be performed in two stages, with different cohorts of patients in each stage.
Phase 3 Trials
Monoclonal Antibodies
Chemotherapy + Atezolizumab for Breast Cancer
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial is studying whether a combination of the standard chemotherapy regimen for breast cancer plus the experimental drug atezolizumab is more effective than the standard chemotherapy regimen plus a placebo.
Cancer Vaccine
Adagloxad Simolenin + OBI-821 for Triple Negative Breast Cancer
Recruiting2 awardsPhase 3
Harbor City, California
This trial is testing a new treatment that combines two substances to help the immune system fight a specific type of high-risk breast cancer. It focuses on patients whose cancer does not respond well to usual treatments.
Chemotherapy
Niraparib for Breast Cancer
Recruiting1 awardPhase 3
Skokie, Illinois
This trial is testing Niraparib, a drug that stops cancer cells from fixing their broken DNA, in patients with certain types of breast cancer that are either genetically aggressive or have signs of remaining disease after treatment. Niraparib is a drug already used for ovarian cancer and has shown promise in treating breast cancer with certain genetic markers.
Trials With No Placebo
Monoclonal Antibodies
SGN-B7H4V for Advanced Cancers
Recruiting1 awardPhase 1
Denver, Colorado
This trial tests a new drug called SGN-B7H4V for safety and side effects in patients with advanced or metastatic solid tumors. It aims to find the right dosage and see if the drug can effectively treat their cancer.
Monoclonal Antibodies
MK-7684A for Advanced Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Chemotherapy
BMS-986340 + Nivolumab/Docetaxel for Cancer
Recruiting1 awardPhase 1 & 2
Hackensack, New Jersey
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
Immune Checkpoint Inhibitor
Olaparib + Pembrolizumab for Breast Cancer
Recruiting1 awardPhase 2
Monterey, California
This trial is comparing the efficacy of two different treatments for triple negative breast cancer - olaparib plus pembrolizumab versus chemotherapy plus pembrolizumab. The primary hypotheses are that olaparib plus pembrolizumab will be superior to chemotherapy plus pembrolizumab in terms of progression-free survival and overall survival.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.